Cargando…

Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury

INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Ta, Yang, Chih-Chau, Zhen, Yen-Yi, Wallace, Christopher Glenn, Yang, Jenq-Lin, Sun, Cheuk-Kwan, Tsai, Tzu-Hsien, Sheu, Jiunn-Jye, Chua, Sarah, Chang, Chia-Lo, Cho, Chung-Lung, Leu, Steve, Yip, Hon-Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706768/
https://www.ncbi.nlm.nih.gov/pubmed/23726287
http://dx.doi.org/10.1186/scrt212
_version_ 1782276401779441664
author Chen, Yen-Ta
Yang, Chih-Chau
Zhen, Yen-Yi
Wallace, Christopher Glenn
Yang, Jenq-Lin
Sun, Cheuk-Kwan
Tsai, Tzu-Hsien
Sheu, Jiunn-Jye
Chua, Sarah
Chang, Chia-Lo
Cho, Chung-Lung
Leu, Steve
Yip, Hon-Kan
author_facet Chen, Yen-Ta
Yang, Chih-Chau
Zhen, Yen-Yi
Wallace, Christopher Glenn
Yang, Jenq-Lin
Sun, Cheuk-Kwan
Tsai, Tzu-Hsien
Sheu, Jiunn-Jye
Chua, Sarah
Chang, Chia-Lo
Cho, Chung-Lung
Leu, Steve
Yip, Hon-Kan
author_sort Chen, Yen-Ta
collection PubMed
description INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equally divided into group 1 (sham controls), group 2 (IR injury), group 3 (IR + CsA (20 mg/kg at 1 and 24 hours after procedure)), group 4 (syngeneic ADMSC (1.2×10(6)) at 1, 6 and 24 hours after procedure), and group 5 (IR + CsA-ADMSC). RESULTS: By 72 hours after the IR procedure, the creatinine level and the ratio of urine protein to creatinine were highest in group 2 and lowest in group 1, and significantly higher in groups 3 and 4 than in group 5 (all P <0.05 for inter-group comparisons), but showed no differences between groups 3 and 4 (P >0.05). The inflammatory biomarkers at mRNA (matrix metalloproteinase-9, RANTES, TNF-α), protein (TNF-α, NF-κB, intercellular adhesion molecule-1, platelet-derived growth factor), and cellular (CD68(+)) levels of IR kidney showed a similar pattern compared with that of creatinine in all groups (all P <0.05 for inter-group comparisons). The protein expressions of oxidative stress (oxidized protein), reactive oxygen species (NADPH oxidases NOX-1, NOX-2), apoptosis (Bcl-2–associated X protein, caspase-3 and poly(ADP-ribose) polymerase) and DNA damage (phosphorylated H2A histone family member X-positive, proliferating cell nuclear antigen-positive cells) markers exhibited a pattern similar to that of inflammatory mediators amongst all groups (all P <0.05 for inter-group comparisons). Expressions of antioxidant biomarkers at cellular (glutathione peroxidase, glutathione reductase, heme oxygenase-1 (HO-1)) and protein (NADPH dehydrogenase (quinone)-1, HO-1, endothelial nitric oxide synthase) levels, and endothelial progenitor cell markers (C-X-C chemokine receptor type 4-positive, stromal cell-derived factor-1α-positive) were lowest in groups 1 and 2, higher in groups 3 and 4, and highest in group 5 (all P <0.05 for inter-group comparisons). CONCLUSION: Combination therapy using CsA plus ADMSCs offers improved protection against acute IR kidney injury.
format Online
Article
Text
id pubmed-3706768
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37067682013-07-15 Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury Chen, Yen-Ta Yang, Chih-Chau Zhen, Yen-Yi Wallace, Christopher Glenn Yang, Jenq-Lin Sun, Cheuk-Kwan Tsai, Tzu-Hsien Sheu, Jiunn-Jye Chua, Sarah Chang, Chia-Lo Cho, Chung-Lung Leu, Steve Yip, Hon-Kan Stem Cell Res Ther Research INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equally divided into group 1 (sham controls), group 2 (IR injury), group 3 (IR + CsA (20 mg/kg at 1 and 24 hours after procedure)), group 4 (syngeneic ADMSC (1.2×10(6)) at 1, 6 and 24 hours after procedure), and group 5 (IR + CsA-ADMSC). RESULTS: By 72 hours after the IR procedure, the creatinine level and the ratio of urine protein to creatinine were highest in group 2 and lowest in group 1, and significantly higher in groups 3 and 4 than in group 5 (all P <0.05 for inter-group comparisons), but showed no differences between groups 3 and 4 (P >0.05). The inflammatory biomarkers at mRNA (matrix metalloproteinase-9, RANTES, TNF-α), protein (TNF-α, NF-κB, intercellular adhesion molecule-1, platelet-derived growth factor), and cellular (CD68(+)) levels of IR kidney showed a similar pattern compared with that of creatinine in all groups (all P <0.05 for inter-group comparisons). The protein expressions of oxidative stress (oxidized protein), reactive oxygen species (NADPH oxidases NOX-1, NOX-2), apoptosis (Bcl-2–associated X protein, caspase-3 and poly(ADP-ribose) polymerase) and DNA damage (phosphorylated H2A histone family member X-positive, proliferating cell nuclear antigen-positive cells) markers exhibited a pattern similar to that of inflammatory mediators amongst all groups (all P <0.05 for inter-group comparisons). Expressions of antioxidant biomarkers at cellular (glutathione peroxidase, glutathione reductase, heme oxygenase-1 (HO-1)) and protein (NADPH dehydrogenase (quinone)-1, HO-1, endothelial nitric oxide synthase) levels, and endothelial progenitor cell markers (C-X-C chemokine receptor type 4-positive, stromal cell-derived factor-1α-positive) were lowest in groups 1 and 2, higher in groups 3 and 4, and highest in group 5 (all P <0.05 for inter-group comparisons). CONCLUSION: Combination therapy using CsA plus ADMSCs offers improved protection against acute IR kidney injury. BioMed Central 2013-05-31 /pmc/articles/PMC3706768/ /pubmed/23726287 http://dx.doi.org/10.1186/scrt212 Text en Copyright © 2013 Chen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Chen, Yen-Ta
Yang, Chih-Chau
Zhen, Yen-Yi
Wallace, Christopher Glenn
Yang, Jenq-Lin
Sun, Cheuk-Kwan
Tsai, Tzu-Hsien
Sheu, Jiunn-Jye
Chua, Sarah
Chang, Chia-Lo
Cho, Chung-Lung
Leu, Steve
Yip, Hon-Kan
Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title_full Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title_fullStr Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title_full_unstemmed Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title_short Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
title_sort cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706768/
https://www.ncbi.nlm.nih.gov/pubmed/23726287
http://dx.doi.org/10.1186/scrt212
work_keys_str_mv AT chenyenta cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT yangchihchau cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT zhenyenyi cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT wallacechristopherglenn cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT yangjenqlin cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT suncheukkwan cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT tsaitzuhsien cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT sheujiunnjye cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT chuasarah cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT changchialo cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT chochunglung cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT leusteve cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury
AT yiphonkan cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury